Bal Pharma Limited (BOM:524824)
India · Delayed Price · Currency is INR 107.47
+1.12 (1.05%)
At close: Sep 11, 2026
Bal Pharma Ratios and Metrics
Market cap in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Total Valuation
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 10, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
| 1,711 | 957 | 1,314 | 1,432 | 1,050 | 1,599 | |
Market Cap Growth | 21.44% | -27.15% | -8.20% | 36.34% | -34.31% | 100.65% |
Enterprise Value | 3,214 | 2,415 | 2,637 | 2,758 | 2,031 | 2,558 |
Last Close Price | 107.47 | 60.14 | 82.04 | 89.23 | 64.76 | 103.32 |
Price Ratios
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 10, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
PE Ratio | 23.87 | 15.24 | 18.22 | 19.37 | 40.83 | 28.49 |
PS Ratio | 0.51 | 0.31 | 0.43 | 0.42 | 0.35 | 0.57 |
PB Ratio | 2.08 | 1.16 | 1.70 | 1.99 | 1.65 | 2.73 |
P/TBV Ratio | 2.63 | 1.24 | 1.81 | 2.14 | 1.79 | 2.93 |
P/FCF Ratio | 13.93 | 7.80 | 37.27 | 12.11 | - | 8.72 |
P/OCF Ratio | 5.55 | 3.11 | 6.47 | 6.28 | - | 5.97 |
EV Ratios
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 10, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
EV/Sales Ratio | 0.96 | 0.78 | 0.87 | 0.81 | 0.67 | 0.91 |
EV/EBITDA Ratio | 9.22 | 9.59 | 10.23 | 9.75 | 8.54 | 11.64 |
EV/EBIT Ratio | 14.31 | 12.67 | 13.17 | 12.75 | 11.66 | 17.13 |
EV/FCF Ratio | 26.17 | 19.67 | 74.77 | 23.32 | - | 13.96 |
Financial Efficiency
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 10, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Debt / Equity Ratio | 1.94 | 2.03 | 1.97 | 1.98 | 2.09 | 1.82 |
Debt / EBITDA Ratio | 4.58 | 6.16 | 5.61 | 4.84 | 5.40 | 4.68 |
Debt / FCF Ratio | - | 13.57 | 43.19 | 12.03 | - | 5.82 |
Net Debt / Equity Ratio | 1.83 | 1.91 | 1.83 | 1.70 | 1.97 | 1.72 |
Net Debt / EBITDA Ratio | 4.31 | 6.25 | 5.51 | 4.32 | 5.28 | 4.59 |
Net Debt / FCF Ratio | - | 12.82 | 40.24 | 10.34 | -7.76 | 5.50 |
Asset Turnover | - | 0.88 | 0.93 | 1.07 | 1.06 | 1.12 |
Inventory Turnover | - | 1.49 | 1.71 | 2.13 | 2.07 | 2.56 |
Quick Ratio | - | 0.45 | 0.48 | 0.61 | 0.50 | 0.52 |
Current Ratio | - | 1.05 | 1.07 | 1.15 | 1.09 | 1.11 |
Return on Equity (ROE) | - | 7.92% | 9.69% | 10.98% | 4.29% | 10.20% |
Return on Assets (ROA) | - | 3.35% | 3.82% | 4.27% | 3.80% | 3.73% |
Return on Invested Capital (ROIC) | 9.51% | 8.30% | 9.68% | 9.28% | 5.51% | 5.76% |
Return on Capital Employed (ROCE) | - | 15.10% | 17.20% | 18.50% | 16.80% | 15.70% |
Yields
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 10, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Earnings Yield | 4.21% | 6.56% | 5.49% | 5.16% | 2.45% | 3.51% |
FCF Yield | 7.18% | 12.83% | 2.68% | 8.26% | -15.41% | 11.46% |
Dividend Yield | 1.36% | 1.99% | 1.46% | 1.34% | 1.54% | 0.97% |
Payout Ratio | - | 30.40% | 26.48% | 21.22% | 60.55% | 26.41% |
Buyback Yield / Dilution | -2.39% | -0.42% | -0.74% | -0.30% | -5.86% | -4.39% |
Total Shareholder Return | -1.03% | 1.57% | 0.73% | 1.04% | -4.31% | -3.42% |